Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC
Posted: March 1, 2019
In the following interview, Jamie E. Chaft, MD, a medical oncologist at the Memorial Sloan Kettering Cancer Center, discusses new data...
Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care
By Kara Nyberg, PhD
Posted: August 2018
Treatment advances for metastatic squamous cell carcinoma have long lagged behind those for other NSCLC subtypes, forcing patients with...
Bringing Lung Cancer Screening into Communities: An NHS Pilot Program’s Success
By Richard Booton, MD, PhD, FRCP
Posted: April 1, 2019
The symptomatic presentation of lung cancer is typically associated with advanced disease and poor survival. Screening asymptomatic...
Changing Landscape of Front-line Immunotherapy
By Naiyer A. Rizvi
The rapid development of anti-PD-1 and PD-L1 antibodies in cancer underscores the tremendous impact they have had on the cancer landscape...
PACIFIC Flooded Us with Optimism. Now What?
By Mirjana Rajer, MD, PhD
Posted: April 1, 2019
For many years, the treatment of patients with stage III lung cancer has been a topic of intense...
Update on Checkpoint Inhibitors in Lung Cancer
By Erik J. MacLaren, PhD
The growing number of checkpoint inhibitors currently being developed, without question, has ushered in a new era in clinical oncology,...
Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC...
Posted: February 2017
By Melody Watson
The first plenary session on the last day of IASLC WCLC 2016 covered one of the most exciting areas in...
Letter to the Editor: Previously Excluded Patients with Autoimmune Disorders, HIV, and More
Letter to the Editor: Opening Trials to Patients Living with HIV
By Armelle Lavolé, AP-HP Hôpital Tenon, Paris, France
Posted: August 14, 2019
In response to the...
Exploring the Potential of Immuno-oncology Combination Therapy
By Cynthia L. Kryder, MS, CCC-Sp
Posted: October 2017
Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy,...
PD-L1 Blueprint Project
Posted: February 2017
By Fred R. Hirsch, MD, PhD
In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In...
